HCA Healthcare, Inc. (HCA) is currently trading at $435.61. Based on 22 Wall Street analysts, the average target price is $454.23, implying a 4.3% upside. The consensus recommendation is BUY.

Over the past 30 days, the feed records 1 target raise and 0 target cuts for HCA. Over the past 90 days, the feed records 2 target raises and 16 target cuts for HCA.

HCA

HCA Healthcare, Inc.

HealthcareOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$435.61

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$380.00$579.00
Current $435.61
Median: $435.00Mean: $450.90Current: $435.61

Recent price target updates (latest 80)

  • BMO CapitalSep 23, 2026

    PT action: Announces

    $0.00 → $495.00

  • Leerink PartnersSep 18, 2026

    PT action: Maintains

    $492.00 → $492.00

  • RBC CapitalSep 8, 2026

    PT action: Maintains

    $435.00 → $435.00

  • JP MorganAug 20, 2026

    PT action: Lowers

    $490.00 → $425.00

  • Wells FargoAug 3, 2026

    PT action: Raises

    $369.00 → $381.00

  • Goldman SachsJul 28, 2026

    PT action: Lowers

    $558.00 → $485.00

  • MizuhoJul 28, 2026

    PT action: Lowers

    $525.00 → $475.00

  • UBSJul 27, 2026

    PT action: Lowers

    $635.00 → $579.00

  • Morgan StanleyJul 27, 2026

    PT action: Lowers

    $425.00 → $380.00

  • RBC CapitalJul 27, 2026

    PT action: Maintains

    $435.00 → $435.00

  • Truist SecuritiesJul 27, 2026

    PT action: Lowers

    $535.00 → $495.00

  • OppenheimerJul 27, 2026

    PT action: Lowers

    $520.00 → $485.00

  • KeybancJul 27, 2026

    PT action: Lowers

    $475.00 → $435.00

  • BairdJul 27, 2026

    PT action: Lowers

    $396.00 → $393.00

  • BarclaysJul 27, 2026

    PT action: Lowers

    $402.00 → $387.00

  • BarclaysJul 16, 2026

    PT action: Lowers

    $427.00 → $402.00

  • RBC CapitalJul 15, 2026

    PT action: Lowers

    $534.00 → $435.00

  • KeybancJul 14, 2026

    PT action: Lowers

    $510.00 → $475.00

  • Wells FargoJul 13, 2026

    PT action: Lowers

    $436.00 → $428.00

  • BarclaysJul 8, 2026

    PT action: Lowers

    $496.00 → $427.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$454.23

Based on 22 analysts

Analyst Recommendations

Buy (15)Hold (10)Sell (1)

Upside

+4.27%

Market Cap

$94.31B

Financial & Investment Metrics

Next Earnings Date
Oct 23, 2026D-27
P/E Ratio (TTM)14.60
Forward P/E13.61
P/B RatioN/A
Dividend Yield0.72%
Return on Equity (ROE)N/A
Operating Margin15.16%
Debt to EquityN/A
Beta (Volatility)1.11
52 Week Range$353.99 - $556.52
LowCurrent: $435.61High

Daily editorial mentioning HCA

Price target moves

Financials and Tech Dominate Price Target Revisions as of July 16

The mid-week session saw a flurry of analyst activity across the S&P 500, with financial services and information technology firms capturing the bulk of the attention. As of the data recorded on July 16, 2026, the desks were particularly busy recalibrating expectations for heavyweights like Microsoft and a suite of banking institutions. While some firms leaned into the bullish outlooks for the tech sector, others took a more cautious stance, leading to a divergent set of target adjustments that highlight a split perspective on market momentum.

Who moved targets

The financial sector saw a string of positive revisions, suggesting analysts are finding more value in big banks as the year progresses. BMO Capital was front and center, pushing up targets for Goldman Sachs (from 1070 to 1190) and Visa (from 375 to 387). Baird followed suit, issuing upward adjustments for Wells Fargo, JPMorgan, and Bank of America, signaling a consistent sentiment across the banking landscape.

Tech names also saw significant volatility in target pricing. Mizuho, for example, made a bold statement on Fortinet by raising its target from 86 to 125, while simultaneously trimming its outlook for Microsoft. It is a common occurrence to see firms diverge on the same asset; for instance, while Evercore ISI Group raised its target on Microsoft to 525, both Mizuho and Citigroup pulled back their respective targets for the software titan to 490 and 570. Elsewhere, Tigress Financial delivered a massive jump for Palo Alto Networks, moving from 245 to 430.

Ticker Firm Direction Prior → Current
FTNT Mizuho Up 86 → 125
PANW Tigress Financial Up 245 → 430
BSX Mizuho Down 90 → 70
HCA RBC Capital Down 534 → 435

Reading the revisions

The downward movement was not limited to tech. Healthcare and energy saw notable pruning, with Mizuho adjusting Boston Scientific (from 90 to 70) and RBC Capital lowering HCA Healthcare by nearly 100 points, landing at 435. These adjustments are essential to track because they often reflect a tightening of earnings expectations in current market moves.

Energy names like Devon Energy, APA Corporation, and PR also faced downward pressure from UBS and Citigroup. Even consumer-facing stalwarts were not immune, as Citigroup opted to lower its target on McDonald’s from 375 to 335. This wave of downgrades serves as a reality check for investors, reminding us that consensus targets are moving targets, frequently reacting to sector-specific margin pressures or macroeconomic shifts. Observing these shifts in real-time provides a clearer picture of how institutional analysts are weighing the balance between growth potential and current valuation realities.

Read article →

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 0Insider Sells: 0

Whale Trades (C-Level Large Buys)

No major insider buying detected recently.

Frequently Asked Questions

Q. What is the current target price and upside for HCA?

A. The current target price for HCA Healthcare, Inc. is $454.23, which implies a 4.3% upside from the current price of $435.61. This is based on the consensus of 22 Wall Street analysts.

Q. What is the current analyst recommendation for HCA?

A. Currently, there are 1 Strong Buy, 14 Buy, 10 Hold, 1 Sell, and 0 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying HCA stock recently?

A. Over the past 6 months, there have been 0 insider buys and 0 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Healthcare

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer →